

Special Issue

Present and Future Perspectives of Vascular Interventional Radiology

Message from the Guest Editor

In recent years, major progress has been made in interventional radiology which has allowed the development of minimally invasive therapeutic alternatives with fewer complications for patients not eligible for conventional treatments. Initially reserved for last-resort treatments, interventional radiology now offers alternative therapies from the early stages of disease. New therapies are emerging and are becoming more and more personalized to the pathology, its stage, and the patient's characteristics. Several emerging themes are being developed in vascular interventional radiology with, for example, osteoarticular embolization for the treatment of chronic pain, prostatic artery embolization in the treatment of benign prostatic hypertrophy, and new focal therapies in oncology. Welcome original research articles and reviews in (not limited):

- Fundamental study of the mechanisms of endovascular ischemia;
- Micro and macro analysis of the response to endovascular ischemia;
- New therapies by controlled endovascular ischemia;
- Structure, organization and quality evaluation (X-ray dose optimization) of these new vascular therapies.

Guest Editor

Dr. Julien Frandon

Department of Medical Imaging, Nîmes University Hospital, University of Montpellier, Nîmes, France

Deadline for manuscript submissions

closed (5 June 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/117155

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).